Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older

BACKGROUND: To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life. METHODS: The assessments were integrated in two Phase III trials, ZOE-5...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Gerontol A Biol Sci Med Sci
Glavni autori: Curran, Desmond, Oostvogels, Lidia, Heineman, Thomas, Matthews, Sean, McElhaney, Janet, McNeil, Shelly, Diez-Domingo, Javier, Lal, Himal, Andrews, Charles, Athan, Eugene, Berglund, Johan, Campora, Laura, de Looze, Ferdinandus, Korhonen, Tiina, Leung, Edward, Levin, Myron, Volpi, Antonio, Johnson, Robert W
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
The Journal of Gerontology: Translational Section
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6625590/
https://ncbi.nlm.nih.gov/pubmed/29955836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/gerona/gly150
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items